Supply Chain Ecosystem Analysis now part of DBMR Reports
Market Size in USD Billion
| 2022 –2029 | |
|
|
USD 690.40 Billion |
| USD 1,127.25 Billion | |
| % | |
|
Global Recombinant Technology Market, By Product (Medical, Non-Medical), Component (Expression System, Cloning Vector), Application (Food and Agriculture, Health and Disease, Environment, Others), End Use (Biotechnology and Pharmaceutical Companies, Academic and Government Research Institutes, Diagnostic Laboratories) – Industry Trends and Forecast to 2029.
Recombinant technology is rapidly being used to treat many illnesses, notably through creating novel pharmaceuticals and vaccinations. This is one of the key drivers of the market, along with the advancement of treatment methods brought on by the development of diagnostic tools, monitoring systems, and new therapy modalities, among others. Additionally, the market for recombinant technology is being driven by the increase in research on genetically modified organisms (GMOs), which include microorganisms thought to be bio degraders and producers of clean fuel.
Data Bridge Market Research analyses that the recombinant technology market which was USD 690.4 billion in 2021, would rocket up to USD 1127.25 billion by 2029, and is expected to undergo a CAGR of 6.32% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product (Medical, Non-Medical), Component (Expression System, Cloning Vector), Application (Food and Agriculture, Health and Disease, Environment, Others), End Use (Biotechnology and Pharmaceutical Companies, Academic and Government Research Institutes, Diagnostic Laboratories)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Amgen Inc (U.S.), Novartis AG (Germany), Novo Nordisk A/S (Denmark), Sanofi (France), Merck & Co., Inc. (U.S.), Genentech, Inc. (U.S.), GenScript (U.S.), Pfizer Inc. (U.S.), Biocon (India), GlaxoSmithKline plc. (U.K.), New England Biolabs (U.K.) Ltd. (U.K.), Cibus (U.S.), Horizon Discovery Ltd. (U.K.), Boehringer Ingelheim International GmbH (Germany), Thermo Fisher Scientific Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Recombinant technology is also known as genetic engineering. It is currently utilized frequently to modify genetic material outside of an organism to produce better and desirable features in living things. It involves inserting DNA fragments from various sources that have the desired gene sequence into a suitable vector. In addition, it helps in the safe, economical, and sufficient manufacturing of essential proteins needed for nutrition and battling health issues. As a result, it has applications across various fields and a great potential to enhance food resources, improve health, and increase resilience to various negative environmental effects.
Drivers
The recombinant technology market is expected to grow at a faster rate during the forecast period 2022 and 2029 due to factors including the expanding biopharmaceutical industry, an increase in technological advancement in the area, a rise in the awareness of human and animal health, and an increase in the success rate of recombinant insulin. On the other hand, government funding for recombinant technology in gene therapy, clinical diagnosis, and pharmaceutical production will create a wealth of growth prospects for the recombinant technology market during the forecast period.
The rise in high-tech goods, the expansion of regulatory approvals, the high prevalence of infectious diseases, and the increased market penetration of major companies all contribute to the increased need for recombinant vaccines globally. The market is expanding due to improving healthcare awareness, attractive reimbursement policies, drug and vaccine research and development innovation, rising average individual incomes, and more.
Opportunities
Ongoing research studies fuel the market's growth to explore the potential of plant as expression system are expected to drive the adoption of plan expression systems for GM product development in the coming years. This will provide beneficial opportunities for market growth.
Moreover, an increase in the number of emerging markets and new product launches will further provide beneficial opportunities for the recombinant technology market growth during the forecast period.
Restraints/Challenges
On the other hand, the scientific, regulatory and ethical challenges along with rising risk in using the genetically modified food will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the recombinant technology market.
Market growth is likely to be impeded by factors such as high vaccine costs, risks associated with live attenuated vaccines, as well as sore throat irritability after vaccine administration, and strict regulatory policies.
This recombinant technology market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the recombinant technology market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
The global pandemic COVID-19 has caused stress across many businesses and industry verticals, not just for human lives. Several million people around the world have contracted the COVID-19 disease, and with more cases becoming active every day, it is still difficult to forecast how long the pandemic will last. The COVID-19 outbreak has had a significant impact on recombinant technology. However, because vaccines are so effective at preventing fatal illnesses, their business has been expanding globally. The prognosis for the year predicts that increased R&D will result in the potential development of a COVID-19 recombinant vaccine.
Recent Development
The recombinant technology market is segmented on the basis of product, component, application and end use. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
Component
Application
End Use
The recombinant technology market is analysed and market size insights and trends are provided by country, product, component, application and end use as referenced above.
The countries covered in the recombinant technology market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the recombinant technology market due to the prevalence of various biopharmaceutical companies along with the high adoption of advanced technology.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the prevalence of low-cost manufacturing centres.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The recombinant technology market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for recombinant technology market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Global recombinant technology market. The data is available for historic period 2010-2020.
The recombinant technology market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to recombinant technology market.
Some of the major players operating in the recombinant technology market are:
SKU-
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.